Recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) vs hydroxycamptothecin
Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found